<DOC>
	<DOCNO>NCT01166737</DOCNO>
	<brief_summary>It still clear whether positive AGO-score select patient less aggressive biologic tumor behavior well would positive outcome chemotherapy , , score select patient really benefit surgery . Nevertheless , AGO-score confirm select patient le 30 % risk end residual tumor surgery recurrent disease . This could avoid include patient present surgical protocol could benefit operationThe goal third DESKTOP study evaluate prospectively randomize multicentre setting , whether maximum effort cytoreductive surgery follow platinum base combination chemotherapy improve overall survival compare platinum base combination chemotherapy alone AGO-score positive patient .</brief_summary>
	<brief_title>Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone Recurrent Platinum-Sensitive Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Patients first recurrence platinum sensitive , invasive epithelial ovarian , fallopian tube primary peritoneal cancer initial stage . Progressionfree interval least 6 month end last platinumcontaining therapy , recurrence within 6 month later primary surgery patient receive prior chemotherapy patient FIGO I . Non cytostatic maintenance therapy contain platinum consider calculation . A positive AGOscore . Obligatory requirement positive AGO recurrence score platinumsensitive disease : 1 . Performance status ECOG 0 2 . No residual tumor primary surgery ( unknown , alternatively primary FIGO stage I/II ) . If report 1st surgery available contact study chairman decide whether inclusion possible . 3 . Absence ascites ( cut &lt; 500 ml : radiological ultrasound estimation ) Complete resection tumor median laparotomy seem possible Patients give sign write informed consent consent data transmission processing . Patients nonepithelial tumor well borderline tumor . Patients without recurrence schedule diagnostic/secondlook surgery debulking surgery completion chemotherapy More one prior chemotherapy Patients second , third , late recurrence Patients second malignancy treat laparotomy , well neoplasms , treatment might interfere treatment relapsed ovarian cancer major impact prognosis expect . Patients socalled platinumrefractory tumor , i.e . progression chemotherapy recurrence within 6 month end former first platinumcontaining therapy Only palliative surgery plan Radiological sign suggest metastasis accessible surgical removal ( i.e . complete resection deem impossible ) Any concomitant disease allow surgery and/or chemotherapy Any medical history indicate excessive perioperative risk Any current medication induce considerable surgical risk ( e.g . bleeding : due oral anticoagulating agent , bevacizumab )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Cancer fallopian tube</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>Recurrent disease</keyword>
	<keyword>Platinum-sensitive</keyword>
	<keyword>Surgery</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Quality Life</keyword>
	<keyword>First recurrence platinum sensitive :</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Peritoneal Cavity Cancer</keyword>
</DOC>